CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

22-304

MEDICAL REVIEW(S)

FDA CENTER FOR DRUG EVALUATION AND RESEARCH
DIVISION OF ANALGESIA, ANESTHESIA, AND RHEUMATOLOGY PRODUCTS
10903 NEW HAMPSHIRE AVENUE, BLDG 22, SILVER SPRING, MARYLAND 20993

Memorandum: Labeling Addendum

DATE: November 20, 2008

RE: Labeling addendum

NDA: 22-304
Tapentadol

THROUGH: Sharon Hertz, M.D., Deputy Directory, DAARP

FROM: Robert Shibuya, M.D., Medical Team Leader, DAARP
Ellen Fields, M.D., MPH, Medical Team Leader, DAARP

This memorandum will summarize the resolution of three labeling issues for NDA 22-304, tapentadol tablets.

1. Serotonin syndrome
   The clinical trial database was searched for the term "serotonin syndrome" and sign/symptom complexes suspicious for serotonin syndrome, and no cases were identified. The pharmacology of tapentadol reflects primarily selective norephinephrine reuptake inhibition and mu opioid agonism, however there is serotonin reuptake inhibition as well, albeit to a lesser extent. Taken in concert with the potential level of morbidity and mortality associated with serotonin syndrome, we felt that appropriate language regarding serotonin syndrome should be placed into the Warnings and Precautions section of the labeling.

2. Contraindication for concomitant use of monoamine oxidase inhibitors
   Although patients receiving MAOIs were not included in the clinical trials of tapentadol, because of the pharmacology of tapentadol and the applicant's concerns about this risk, this contraindication was included in the product labeling.

3. Medication Guide
In their review of the abuse liability data, the Controlled Substance Staff noted that studies with tapentadol had findings consistent with a very high abuse liability (similar to hydromorphone). Despite the fact that tapentadol is likely to be classified in Schedule II by the Drug Enforcement Administration, additional patient education is considered prudent and necessary to mitigate abuse. Hence, a Medication Guide (and subsequently a REMS) has been added to the labeling for tapentadol.

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Robert Shibuya
11/20/2008 01:36:24 PM
MEDICAL OFFICER

Ellen Fields
11/20/2008 05:25:20 PM
MEDICAL OFFICER

Ellen Fields
11/20/2008 05:25:47 PM
MEDICAL OFFICER

CLINICAL REVIEW N 22-304 Tapentadol

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Anesthesia, Analgesia and Rheumatology Products, HFD-170
10903 New Hampshire Avenue, Silver Spring, MD 20993

Medical Officer Review

Date of Submission:	**January 23, 2008**
Type of Submission:	**New Drug Application**
Product:	**Tapentadol ™**
Sponsor:	**Johnson & Johnson**
Review Date:	**September 18, 2008**
PDUFA Date:	**November 23, 2008**
Reviewer:	**Ellen W. Fields, M.D., M.P.H.** **Clinical Team Leader**
Project Manager:	**Matthew Sullivan**

DOCKET ALARM

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts

Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research

With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips

Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS
Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS
Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS
Sync your system to PACER to automate legal marketing.